EQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Equillium Inc (EQ) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, insider selling, and no significant positive catalysts. While the technical indicators are mixed, the lack of recent positive news, poor financials, and minimal upside potential in the short term suggest holding off on investment for now.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 49.211, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 1.8, with key support at 1.666 and resistance at 1.934.
Stifel analyst initiated a Buy rating with a $5 price target, citing potential in the inflammatory bowel disease market.
No recent news or significant trading trends. Congress trading data shows no activity.
In Q3 2025, revenue dropped to 0 (-100% YoY), net income improved to -$4.23M (+60328.57% YoY), EPS remained at -0.06, and gross margin dropped to 0 (-100% YoY).
Stifel analyst Alex Thompson initiated coverage with a Buy rating and a $5 price target, citing potential in the inflammatory bowel disease market despite the preclinical status of EQ504.
